Active, not recruitingPHASE1, PHASE2NCT03932331

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Principal Investigator: Jun Zhu, Prof
Peking University Cancer Hospital & Institute
Intervention: Acalabrutinib(drug)
Enrollment: 105 enrolled
Eligibility: 18-130 years · All sexes
Timeline: 2020 – 2026

Study locations (19)

Research Site, Beijing, China
Research Site, Changchun, China
Research Site, Changsha, China
Research Site, Changzhou, China
Research Site, Chengdu, China
Research Site, Fuzhou, China
Research Site, Haikou, China
Research Site, Hangzhou, China
Research Site, Harbin, China
Research Site, Hefei, China
Research Site, Hohhot, China
Research Site, Nanchang, China
Research Site, Nanjing, China
Research Site, Shanghai, China
Research Site, Suzhou, China
+4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03932331 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials